You are here

Syneos Health to Present at the 2018 Baird Global Healthcare Conference

RALEIGH, N.C., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Syneos HealthTM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Financial Officer Jason Meggs is scheduled to present at the 2018 Baird Global Healthcare Conference in New York, NY, on Thursday, September 6, 2018, at 12:15 p.m. ET.

A live webcast and archived audio replay of the event, as well as links to the presentation materials, will be available on the Company’s Investor Relations website at investor.syneoshealth.com.

About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 22,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.

Contacts

Investor Relations:
Ronnie Speight
Vice President, Investor Relations
+1 919 745 2745
Investor.Relations@syneoshealth.com

Press/Media:
Danielle DeForge
Executive Director, External Communications
+1 202 210 5992
danielle.deforge@syneoshealth.com

Friday, August 17, 2018 - 09:57

More Headlines

Conversely, Kids Who Need Drugs Go Untreated
May Reduce the Need for Open-Heart Surgery
NDEA, a Known Carcinogen, Discovered During FDA Testing
Cleared for Adults with Relapsed or Refractory Disease
Approved as Maintenance Treatment for Opioid Dependence
Says Company’s OxyContin Had “Significant Role” in Opioid Epidemic
Study Uses Experimental Software to Decode Variations in Mood
Mixup with Losartan Discovered in Bottles